MYOD1 and neoplasm: Treatment of tumor-bearing animals with a non-specific NF-κB inhibitor prevents tumor-associated muscle wasting via increased MyoD expression and inhibition of ubiquitin-conjugating enzyme E214K in skeletal muscles [173].